Peregrine presses on with bavituximab phase III
By Catherine Shaffer
Tuesday, December 31, 2013
As promised, Peregrine Pharmaceuticals Inc. has launched a Phase III trial (SUNRISE) of its lung cancer immunotherapy, bavituximab, in spite of a discouraging Phase II failure.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.